

AD _____

Award Number: DAMD17-03-1-0673

TITLE: Development of a Microfluidic Device for the Study of Breast
Cancer Cell Migration

PRINCIPAL INVESTIGATOR: Wajeeh M. Saadi, M.S.
Noo Li Jeon, Ph.D.

CONTRACTING ORGANIZATION: University of California at Irvine
Irvine, CA 92612

REPORT DATE: September 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060508044

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-09-2005		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 Sep 04 - 31 Aug 05	
4. TITLE AND SUBTITLE Development of a Microfluidic Device for the Study of Breast Cancer Cell Migration				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0673	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Wajeeh M. Saadi, M.S. Noo Li Jeon, Ph.D. E-Mail: wsaadi@uci.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California at Irvine Irvine, CA 92612				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT This project focuses on the development of microfluidic chambers for the study of breast cancer cell chemotaxis. We are continuing our work on characterizing breast cancer cell chemotaxis in epidermal growth factor (EGF) gradients. We developed a parallel-gradient microfluidic chemotaxis chamber, allowing different gradients to be generated side by side. Using this chamber, we compared the effects of different EGF gradients on breast cancer cell chemotaxis, and observed subtle different in the migratory response. We also characterized the effect of an EGFR antagonist on chemotaxis. As we move forward in this project, we will continue to investigate breast cancer cell chemotaxis in different gradient conditions and different chemoattractants.					
15. SUBJECT TERMS Cell Migration, Chemotaxis, Metastasis, Microfabrication					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 28	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusions.....	6
References.....	7

Introduction

This report describes our accomplishments so far in the development of microfluidic devices for the study of breast cancer cell chemotaxis. We have previously demonstrated the chemotaxis of breast cancer cells in epidermal growth factor (EGF) gradients, and found that gradient shape plays an important role in determining the response. We are continuing our work on characterizing breast cancer cell chemotaxis in EGF gradients. We developed a parallel-gradient microfluidic chemotaxis chamber, allowing different gradients to be generated side by side. Using this chamber, we compared the effects of different EGF gradients on breast cancer cell chemotaxis, and observed subtle differences in the migratory response. We also characterized the effect of an EGF receptor (EGFR) antagonist on breast cancer cell chemotaxis in EGF gradients.

Body

In order to perform accurate and in-depth analysis of chemotaxis in different gradient conditions, we developed a parallel-gradient microfluidic chemotaxis chamber, allowing different gradients to be generated side by side. This allows us to compare the migratory responses of cells in different conditions side by side, with a high degree of control. Using this parallel-gradient chamber, we studied the chemotaxis of MDA-MB-231 in EGF gradients of different ranges. We compared a 0-50 ng/ml EGF polynomial gradient, which we previously showed to be potent in inducing chemotaxis, with a shallower 0.1-6 ng/ml EGF polynomial gradient. We found that although the chemotactic response is weaker in the shallower gradient, cells still migrated

directionally. Comparing the responses side by side, we were able to observe subtle differences in migratory behavior of the cells. In particular, we found that motility in both ranges is similar (as indicated by similar speeds), but that directional orientation is different.

We also investigated the effect of an anti-EGFR antibody on chemotaxis MDA-MB-231 in EGF gradients, comparing antibody-treated cells with control cells side by side. We found that the anti-EGFR antibody abolishes the chemotactic response, inhibiting both motility and directional orientation. Such detailed analysis of migration in the presence of antagonists can have important applications in the development and characterization of inhibitors for the treatment of breast cancer metastasis. Please see the attached manuscript (Saadi et al.) for more details.

Key Research Accomplishments

- Developed a parallel-gradient chemotaxis chamber allowing detailed analysis of breast cancer cell chemotaxis in different gradients simultaneously
- Investigated the migration of the human metastatic breast cancer cell line MDA-MB-231 in shallow and steep polynomial gradients of epidermal growth factor (EGF)
 - Showed that EGF is a potent chemoattractant for MDA-MB-231 cells, capable of inducing chemotaxis even in shallow gradients
 - Showed that the motility is similar in both gradient ranges (shallow and steep), but that directional orientation is different.

- Investigated the effect of an anti-EGFR antibody on the migration of MDA-MB-231 cells in EGF gradients
 - Showed that anti-EGFR inhibits both motility and directional orientation.

Reportable Outcomes

- Presentation:

W. Saadi, S.-J. Wang, F. Lin, and N.L. Jeon.

Chemotaxis of Metastatic Breast Cancer Cells in Parallel-Gradient

Microfluidic Chambers.

Experimental Biology, San Diego, CA, April 2005.

- Manuscript in review:

Saadi W, Wang S-J, Lin F, and Jeon NL. Chemotaxis of Breast Cancer

Cells in Simultaneous Microfluidic Gradients: a new Platform for

Metastasis Research. *In review*. (Attached in Appendix)

Conclusions

We have developed a parallel-gradient microfluidic chamber for the study of breast cancer cell chemotaxis in different gradients side by side. Using this chamber, we characterized the migration of MDA-MB-231 in different gradient ranges of EGF. We also characterized the effect of anti-EGFR antibody on the chemotactic response. Such analysis may find important applications in the development of treatments for breast cancer metastasis.

References

Saadi W, Wang S-J, Lin F, and Jeon NL. Chemotaxis of Breast Cancer Cells in Simultaneous Microfluidic Gradients: a new Platform for Metastasis Research. *In review*. (Attached in Appendix)

Chemotaxis of Breast Cancer Cells in Simultaneous Microfluidic Gradients: a new Platform for Metastasis Research

Wajeeh Saadi^a, Shur-Jen Wang^a, Francis Lin^{ab}, and Noo Li Jeon^{a*}

^a Department of Biomedical Engineering, 204 Rockwell Engineering Center, University of California at Irvine, Irvine, CA, 92697, U.S.A.

Fax: 1 949 824 9968 or 1 949 824 1727; Tel: 1 949 824 9032; E-mail: njeon@uci.edu

^b Department of Physics and Astronomy, University of California at Irvine, Irvine, CA, 92697, U.S.A.

Key words: breast cancer, metastasis, chemotaxis, microfluidics

Abbreviations:

PDMS	poly(dimethylsiloxane)
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
Anti-EGFR	Neutralizing antibody against the epidermal growth factor receptor
CI	Chemotactic index

Journal category: Cancer cell biology

Novelty and impact of the paper:

We report on the development and application of a novel chemotaxis assay based on a microfluidic device that enables quantitative characterization and comparison of cancer cell chemotaxis. We examined the migration of metastatic breast cancer cells in different concentration ranges of EGF, as well as with and without EGFR antibody, in parallel. The parallel gradient-generating chemotaxis chamber shows potential for screening of different inhibitors and drugs that target metastatic cancers, allowing their effects on cell migration to be investigated. This development allows detailed quantitative analysis and comparison of cell migration under various conditions.

Abstract

Growth factor-induced chemotaxis of cancer cells plays a critical role in metastasis, directing the spread of cancer from the primary tumor to secondary sites in the body. Understanding the mechanistic and quantitative behavior of cancer cell migration in growth factor gradients would greatly help in future treatment of metastatic cancers. Using a novel microfluidic chemotaxis chamber capable of simultaneously generating multiple growth factor gradients, we examined the migration of the human metastatic breast cancer cell line MDA-MB-231 in various conditions. First, we quantified and compared the migration in two gradients of epidermal growth factor (EGF) spanning different concentrations: 0-50 ng/ml and 0.1-6 ng/ml. Cells showed a stronger response in the 0-50 ng/ml gradient: 87.4% of the cells moved towards higher EGF concentrations (chemotactic index $CI = 0.29$, speed = $0.94 \mu\text{m}/\text{min}$), while only 62% of cells moved towards higher concentrations in the shallower, 0.1-6 ng/ml gradient ($CI = 0.10$, speed = $0.89 \mu\text{m}/\text{min}$). The fact that even a shallow gradient of EGF can induce chemotaxis, and that EGF can direct migration over a large dynamic range of gradients, confirms the potency of EGF as a chemoattractant. Second, we investigated the effect of antibody against the EGF receptor (EGFR) on MDA-MB-231 chemotaxis. Quantitative analysis indicated that anti-EGFR antibody impaired both motility and directional orientation ($CI = 0.03$, speed = $0.71 \mu\text{m}/\text{min}$), indicating that cell motility was induced by the activation of EGFR. The ability to compare, in terms of quantitative parameters, the effects of different pharmaceutical inhibitors, as well as subtle differences in experimental conditions, will aid in our understanding of mechanisms that drive metastasis. The microfluidic chamber described in this work will provide a platform for cell-based assays that can be used to compare the effectiveness of different pharmaceutical compounds targeting cell migration and metastasis.

Introduction

Cell motility plays an important role in many biological processes, including inflammation¹, wound healing², and cancer metastasis³⁻⁵. Of particular importance in these processes is chemotaxis: directed motility towards increasing concentrations of soluble factors. The study of cell motility and chemotaxis, like any experimental system, is often defined by the assays employed⁶. One of the most commonly used assays is the Boyden chamber (also called transfilter or transwell assay), which measures motility as the number of cells that migrate across a filter between two compartments containing soluble factors⁷. In spite of its popularity, this method does not allow visualization of the actual migration paths, providing only an endpoint measurement. In addition, comparisons of cells with different sizes or different abilities to deform may be inaccurate, since cells have to deform in order to migrate through the pores and cross the filter⁶. Surface assays (such as wound-healing, colony scattering, and under-agarose assays) overcome the deformability problem by allowing cells to migrate on a flat surface, but most are still endpoint assays and cannot always be utilized to study chemotaxis⁶. Visual assay systems allow the details of the motility process to be studied, and allow chemotaxis to be observed, usually in response to pipette tips containing soluble factors, but are generally low throughput, best suited for single-cell measurements⁶.

In addition, a major deficiency of conventional assays is their reliance on free diffusion between a source and a sink to generate concentration gradients, which are in turn unstable and difficult to manipulate^{8,9}. Quantitative descriptions of gradient conditions produced by these methods require complicated mathematical modeling⁹. Consequently, the relationships between various chemical signals and the resulting chemotactic responses of different cells have been difficult to characterize rigorously. Advances in soft lithography and microfluidics enabled the development of chemotaxis chambers that can generate precise, stable concentration gradients, and allow real-time observation of migrating cells^{8,10}. This method was used to investigate the migration of neutrophils and breast cancer cells in IL-8⁹ and epidermal growth factor (EGF)¹¹ gradients. In both cases, the

chemotaxis chambers were used to produce and maintain precise and stable gradient conditions that allowed quantitative characterization of directed cell migration.

In order for the microfluidic assay to be broadly useful in biology, it should easily lend itself to comparative measurements of chemotaxis in different conditions. This requires controls to be performed alongside of experiments, and different experimental conditions to be carried out in parallel. To this end, we developed a parallel-gradient microfluidic chemotaxis chamber that can generate soluble gradients of growth factors side by side, allowing two or more experiments to be carried out simultaneously using one imaging setup. With this capability, we can quantitatively analyze chemotactic responses in different conditions with a high degree of control, allowing us to detect subtle differences with exquisite detail. Using this approach, we first compared the chemotactic response of the cancer cells in two different concentration gradients of EGF; these gradients have the same profile but span different ranges of concentration (0-50 ng/ml and 0.1-6 ng/ml). Both gradients induced chemotaxis, but the response was stronger in the 0-50 ng/ml gradient. This demonstrates that EGF is a potent chemoattractant capable of inducing chemotaxis over a wide range of gradients. We then verified the specificity of the induced chemotactic response using an antibody that blocks the EGF receptor (EGFR). Both motility and directional sensing were lost when EGFR was blocked. These findings have relevance to the metastatic process and therapeutic efforts, and hint at the wealth of information that can be obtained from studies of cancer cell chemotaxis.

Methods

Cell Culture

Leibovitz's L-15 medium, penicillin/streptomycin, trypsin/EDTA, Cell dissociation buffer, and fetal bovine serum (FBS) were purchased from GIBCO (Carlsbad, CA). Recombinant human EGF, bovine serum albumin, and human collagen type IV were purchased from Sigma (St Louis, MO). Mouse monoclonal neutralizing anti-EGFR antibody was purchased from Upstate Biotechnology (Lake Placid, NY). The human metastatic breast cancer cell line, MDA-MB-231, was

obtained from The American Type Culture Collection (ATCC, Manassas, VA) and routinely passaged in L-15 medium supplemented with 10% FBS and penicillin/streptomycin.

Device Fabrication

The microfluidic gradient generator was fabricated in poly(dimethylsiloxane) (PDMS) using soft lithography and rapid prototyping¹². Briefly, a transparency mask with a minimum feature size of ~30 μm was printed using a high-resolution printer (Page One, Irvine, CA) from a CAD file (Freehand, Macromedia, CA). The mask was used in 1:1 contact photolithography of SU-8 photoresist (MicroChem, MA) to generate a negative "master" consisting of 100- μm high patterned photoresist on a Si wafer (Silicon Inc., Boise, ID). Positive replicas with embossed channels were fabricated by molding PDMS (Sylgard 184, Dow Corning, Midland, MI) against the master. The cured PDMS was peeled off the master, and holes were punched with a sharpened needle for fluidic interconnects. The PDMS was sealed against a glass slide upon treating both with an air-plasma (Plasma cleaner Model PDC-001, Harrick Scientific Corporation, Ossining, NY), forming a covalent bond and completing the microfluidic network. All channels were made of PDMS with glass bottoms.

Microfluidics

Prior to the cell migration experiment, the 400- μm wide migration channel was coated with 2 $\mu\text{g}/\text{ml}$ collagen type IV at room temperature for 30 min. The collagen was then removed and the channel was washed twice with distilled water and blocked with 2% BSA at 37°C for 2 hrs or at 4°C overnight. Polyethylene tubing (PE-20, Becton Dickinson, Sparks, MD) was inserted into the inlets and connected to syringe pumps (model 50300, Kloeohn Ltd., Las Vegas, NV) to infuse the solutions through the microfluidic device. The solutions were made up of 0.2% BSA in L-15 medium (0.2% BSA/L-15), with or without growth factor. To visualize the concentration gradient profile of EGF (MW = 6 kDa), 5 μM FITC-dextran (Sigma) with a molecular weight of 10 kDa was added to the EGF solutions. A control experiment with FITC-dextran indicated no effect on migration.

Cell Migration Assay

MDA-MB-231 cells were removed from the culture flask using cell dissociation buffer, washed with 0.2% BSA/L-15, centrifuged down, resuspended in 0.2% BSA/L-15, and filtered through a 40- μ m filter to obtain a suspension of single cells. For the anti-EGFR experiments, cells were counted after they were taken out of the flask, centrifuged down, and resuspended in anti-EGFR solution (in 0.2% BSA/L-15) at a density of 1×10^6 cells/ml prior to filtration. Antibody-treated cells, along with untreated cells, were then incubated on a rotator for 1 hr at room temperature. The cells were loaded into the microfluidic device from the cell port using a micropipette. The flow inside the device was slowed down or stopped to facilitate the attachment of cells to the bottom of the migration channels. Once the cells attached, a flow rate of 1 μ l/min (equivalent to a linear speed of 4.2×10^{-2} cm/s) was applied. For the anti-EGFR experiments, anti-EGFR was added to the solutions flowing over the antibody-treated cells.

Time-lapse differential interference contrast (DIC) images of migrating cells were obtained using an inverted microscope (Nikon, Meville, NY) with a 10X objective. The microscope stage was enclosed in a temperature-controlled box maintained at 37°C. Images were acquired with a CCD camera (Photometrics CoolSNAP cf, Roper Scientific, Tucson, AZ) at 2 min intervals for 3hrs. A computer-controlled motorized stage was used to image multiple positions along the migration channel.

Data Analysis

Time-lapse images of cells were tracked and analyzed using MetaMorph (Universal Imaging, Downingtown, PA). Raw tracking data for each cell were analyzed with a spreadsheet to calculate various migration parameters [(1) net cell displacement (straight length of cell displacement between starting and final positions), (2) total distance (sum of straight-line segments that a cell travels between consecutive images), (3) net displacement towards gradient, (4) speed (total distance divided by time), (5) migration angle (angle of the net cell displacement vector, measured clockwise from the

positive y direction), and (6) chemotactic index (CI, net displacement towards gradient divided by total distance)]. Migration angles are defined with respect to the gradient direction (0° and 180° = net displacement perpendicular to gradient direction, 90° = net displacement completely in the gradient direction, 270° = net displacement completely opposite of gradient direction). CI is a measure of how much of the total movement is directed towards the gradient, ranging from -1 (cell moves completely opposite of gradient direction) through 0 (cell moves perpendicular to gradient direction) to 1 (cell moves completely in the gradient direction).

Statistical analysis of migration angles was performed using Oriana for Windows (Kovach Computing Services, Wales, UK) to examine the directionality of the chemotactic response. Migration angles were summarized in a direction plot, which is a rose diagram showing the distribution of angles grouped in 10° intervals, with the radius of each wedge indicating cell number. The Rayleigh test for circular uniformity was applied, with a significance level of 0.01. When there was significant directionality, the mean angle and the 95% confidence interval were calculated. A Modified Rayleigh test was also applied, in order to test whether deviations from the gradient direction were significant¹³.

The non-linear polynomial gradient (Figure 1a) used in this paper was divided into two regions: a shallow region (positions 0 to 160 μm on the x axis), where the concentration of ligand remains very low; and a steep region (positions 160 to 400 μm on the x axis), where the concentration of ligand increases very rapidly. Cells that were predominantly migrating in the shallow region of the gradient were excluded from the analysis. For each experimental condition, a minimum of 50 cells was analyzed.

Results

Generation of Parallel Gradients

The microfluidic chemotaxis chamber is comprised of a gradient-generating network of channels that merge into the migration channel near the outlet (Figure 1). The design shown in Figure 1a produces a nonlinear polynomial gradient similar in shape to that produced by diffusion from a micropipette, but stable over time. The gradient profile for EGF is indirectly visualized using FITC-dextran, added to the EGF solution. A fluorescence micrograph and a graph showing the gradient profile are shown below the schematic. If a chamber consists of two adjacent networks that merge into one migration channel, two gradients are produced in parallel (Figure 1b). Since the two networks are mirror images of each other, the two gradients are identical in shape but opposite in direction. Figure 1c represents the same parallel-gradient design, with the addition of a physical barrier between the two gradients.

Shallow EGF Concentration Gradient Can Induce Chemotaxis of Metastatic Breast Cancer Cells

EGF has been shown to induce chemotaxis of a variety of cancer cells, including breast cancer cells¹⁴⁻¹⁷. We have previously reported, using a microfluidic chemotaxis chamber, that the shape of EGF gradient determines whether the migration is directed or random¹¹. We found that nonlinear polynomial gradients of EGF induced chemotaxis of MDA-MB-231, while linear gradients resulted in random migration. Under our experimental conditions¹¹, a polynomial gradient of 0-50 ng/ml EGF induced the most pronounced chemotactic response.

To investigate migration in a shallower EGF gradient, we used the parallel-gradient chamber without barrier (Figure 1b). We tested the migration of breast cancer cells in a 0.1-6 ng/ml polynomial EGF gradient alongside a 0-50 ng/ml EGF gradient (Figure 2). In 0-50 ng/ml EGF, cells moved chemotactically, similar to previous findings¹¹ with an average CI of 0.29. Moreover, the Rayleigh test showed significant unimodal clustering of cell trajectories, with a mean angle of 87.4°, in close alignment with the gradient direction (Figure 2b). Cells in the 0.1-6 ng/ml EGF gradient had

a wider distribution of trajectories and a smaller average CI (0.10), but still exhibited preferential directional orientation, with a mean angle of 53.9° (Figure 2c). A modified Rayleigh test¹³ showed that this angle does not significantly deviate from the gradient direction, confirming that the 0.1-6 ng/ml EGF gradient can induce chemotaxis.

Anti-EGFR Inhibits EGF-Induced Chemotaxis in Microfluidic Chamber

The effect of EGFR-blocking antibody on MDA-MD-231 chemotaxis in EGF gradients was examined using the parallel-gradient chamber, with the addition of a barrier (Figure 1c). Migration of cells pretreated with antibody was examined in 0-50 ng/ml EGF alongside untreated control cells. Untreated cells clearly exhibited polarized morphology, characterized by a flat, fan-shaped lamellipod (an extension of the cell membrane at the leading edge) oriented towards increasing EGF concentration (Figure 3). Cells that were treated with antibody, on the other hand, were mostly unpolarized and had no predominant orientation, reflecting random movement. Indeed, the average CI of antibody-treated cells was lower (0.03) than control (0.21) and only 55% of cells moved towards the gradient, compared to 80% in the case of the control (Figure 4). This was confirmed by the Rayleigh test, which showed no directional preference in the distribution of migration angles for antibody-treated cells (Figure 4); untreated control cells exhibited a directional preference, with a mean angle of 74.8° . Again, this deviation from the gradient direction is not statistically significant, as shown by the modified Rayleigh test.

Discussion

Chemotaxis Chamber Design and Layout

Figure 1a shows the design of a microfluidic gradient generator that produces a single gradient of nonlinear polynomial profile¹⁸ (polynomial gradient from here on). The principle behind the generation and control of concentration gradients using microfluidics has been published elsewhere^{8,10}. Briefly, fluid streams are repeatedly split and mixed in the gradient-generating channel network (Figure 1a), the design of which determines the shape of the resulting gradient in the migration channel. For example, a network design with two inlets infused with 0% and 100% solutions yields a 0-100% linear gradient across the migration channel and perpendicular to the flow. Although the network in Figure 1a has two inlets, the left inlet splits into four streams, effectively increasing the number of inlets to five. Infusing the device with media and chemoattractant-containing media into the left and right inlet, respectively, with a volumetric flow rate ratio of 4:1, produces a polynomial concentration gradient of the form:

$$C = ax^{4.2} + b$$

where **C** is the concentration of chemoattractant; **x** is the position across the migration channel; **a** and **b** are constants that depend on the width of the channel as well as the minimum and maximum chemoattractant concentrations.

Each microfluidic network generates a single microfluidic gradient; when two networks are placed in parallel and merged into one channel, two gradients are formed side by side (Figure 1b). The two polynomial gradients in Figure 1b are placed opposite of each other to minimize blurring between the gradients due to diffusion. Alternatively, a physical barrier (Figure 1c) can be used to avoid the blurring interface. A barrier is needed for applications that utilize small molecules (sizes <1 kDa). Relatively large diffusion coefficients of small molecules ($D \approx 5 \times 10^{-5} \text{ cm}^2/\text{s}$) allow them to quickly cross over between adjacent gradients under the flow speeds used in our experiments ($4.2 \times 10^{-2} \text{ cm/s}$). In addition, a barrier is needed for applications that require different pretreatments for

separate group of cells. As illustrated in our example, a barrier would allow antibody-treated cells and control cells to be loaded separately while allowing side by side comparison of their migration.

EGF is a Potent Chemoattractant for Metastatic Breast Cancer Cells

Cancer metastasis is a complex process that involves a number of events, with multiple signals from tumor and stromal cells, the extracellular matrix, and soluble growth factors influencing the behavior of cancer cells^{6, 19-21}. One of the most important, and best understood, growth factor systems in this regard is the EGF/EGFR system, long implicated in cancer development^{5, 16, 22}. Traditionally associated with tumor cell proliferation and growth, EGFR expression has been found to correlate with the metastatic potential of various cancers^{23, 24}. On the cellular level, EGF was shown to induce chemotaxis of metastatic breast cancer cells, both *in vivo*¹⁷ and *in vitro*^{15, 16}. This is particularly relevant to metastasis, since platelets, smooth muscle cells, monocytes, and macrophages have been shown to produce EGF along with platelet-derived growth factor (PDGF) and related growth factors²⁵⁻²⁸. Gradients resulting from the release of these factors may provide chemotactic cues that direct metastatic cell motility towards blood vessels, where they can enter the blood stream and travel to other sites in the body^{3, 28}. In order to understand and subsequently treat metastasis, we need to understand the mechanism of cancer cell chemotaxis in response to EGF and other chemoattractants. To achieve this understanding, we must study chemotaxis in precisely controlled microenvironments, both at the single-cell level as well as the population level, in real time. This kind of detailed information cannot be obtained with conventional methods, which use macroscale diffusion. We present an example of the wealth of data that can be obtained through comparative analysis of cell migration in parallel-gradient microfluidic chemotaxis chambers.

We have previously reported that EGF gradients induce chemotaxis of the human metastatic breast cancer cell line MDA-MB-231¹¹. Unlike other reports, we were able to define and maintain the exact mathematical form of the EGF gradient to which the cells were exposed. We showed that cells migrated chemotactically in polynomial gradients while linear gradients and uniform EGF resulted in random migration¹¹. This previous work demonstrated that breast cancer cells are

sensitive to the profile of EGF gradient they encounter, not simply the slope of the gradient¹¹.

Among the polynomial EGF gradients tested (0-25 ng/ml, 0-50 ng/ml, 0-100 ng/ml), 0-50 ng/ml gradient induced optimal directed migration. Compared to the equilibrium dissociation coefficient of EGF ($k_d = 6$ ng/ml), these gradients span concentrations that are considerably higher. The K_d can be used to model receptor binding kinetics and predict cell responses in different gradients (see Ref 11 for a brief discussion). Based on these considerations, it is necessary to investigate cell migration in gradients that are shallower in range and closer to the k_d value. Considering that growth factors may be released from macrophages or other cells around the blood vessels, the growth factor gradient would be steep, with higher concentrations near the blood vessel. Yet, the growth factor concentration would rapidly decay further away from the blood vessel, establishing a shallow gradient. Considering the widely varying gradient conditions that may exist in tissues, it is important to investigate cancer cell migration in both high and low range concentration gradients.

We compared the migration of breast cancer cells in a 0.1-6 ng/ml polynomial EGF gradient alongside a 0-50 ng/ml EGF gradient (Figure 2). The baseline of the 0.1-6 ng/ml gradient was chosen to be nonzero so that cells in the low end of the gradient would be exposed to more EGF than they would if the baseline was zero. This was done to improve the motility of cells by chemokinesis in the low growth factor region. Otherwise, cell migration in the low end of the gradient would be mostly basal. Figure 2 shows significant net movement towards the gradient in both ranges, with different efficiencies. The average CI and the percentage of cells that moved towards the gradient were lower in 0.1-6 ng/ml EGF, with a wider distribution of migration trajectories and a larger confidence interval. The average speeds in the two gradients were very close, however. This suggests that at some point between 0.1 and 6 ng/ml EGF, the receptors are being saturated, such that higher concentrations do not improve motility. Alternatively, there may be a threshold concentration that is required for inducing motility. The directional response, on the other hand, is clearly dose dependent in the ranges tested, as the shallower gradient induces a weaker response. It must be emphasized that although the mean angles in the two gradients appear to be different, neither of them significantly

deviates from the gradient direction. The observed differences in migration angles are attributed to random variations in the cell population, especially since cancer cells are heterogeneous.

These data demonstrate that EGF induces chemotaxis in metastatic cells over a broad dynamic range of concentrations, and confirms its potency as a chemoattractant¹⁶. These findings may have implications for metastatic cells in the tumor microenvironment. Suppose that metastatic cells are located inside a tumor, at some distance away from a blood vessel, and that EGF is being released from a location near the blood vessel. As mentioned above, we expect the EGF concentration to be relatively high near the blood vessel but low where the metastatic cells are. Detecting a shallow concentration gradient of EGF, the metastatic cells would have a moderate chemotactic response: a fraction of the cells would migrate in the general direction of increasing EGF concentration, while the rest would wander in other directions, with the same migration speed. This behavior may actually be advantageous to the metastasizing tumor cell if we consider a scenario where multiple blood vessels are releasing growth factors, such that the metastatic cells receive conflicting signals from different directions. The fact that a certain number of cells will wander off from a given gradient direction may allow them to explore other gradient-releasing vessels, thus increasing their likelihood of reaching the blood stream and getting disseminated to other sites in the body. As the cell gets closer to a blood vessel, the EGF concentration would increase and the gradient will become steeper, resulting in strong directed migration towards the source and locking the cell in its course towards the blood vessel.

The ability to adapt to a broad range of EGF concentrations may have important implications for therapeutic efforts to treat metastasis. Several approaches are currently being employed to target the EGF/EGFR system (see the following section for more details). These efforts must be armed with a solid understanding of the dose-dependence of EGF-induced motility, such that treatments can be designed most effectively.

Effect of EGFR-Blocking Antibody on Cancer Cell Migration in EGF Gradient

Due to its importance in cancer, several therapeutic strategies have targeted the EGF/EGFR signaling pathway^{29,30}. One strategy has been to use antibodies that compete with the ligands for the receptor; monoclonal antibodies against EGFR have been under development for some time^{31,32}. The humanized monoclonal antibody Erbitux (Cetuximab, C225) was recently approved in the US and Switzerland for the treatment of colorectal cancer. Experimentally, this antibody inhibits the growth of cancer cell lines in culture and inhibits the growth of Xenografted tumors³³. Due to the involvement of EGF in chemotaxis, it is important to investigate the effect of EGFR antibodies on cancer cell migration and chemotaxis.

Using the parallel gradient chamber (Figure 1c), we examined the effect of anti-EGFR treatment on the migration of metastatic breast cancer cells alongside untreated control cells. Antibody treatment abolished the chemotactic response of the cancer cells and resulted in random migration. This is clearly seen in the morphology of antibody-treated cells (Figure 3), which were mostly unpolarized. Untreated cells, on the other hand, had well defined lamellipodia that were oriented towards increasing EGF concentration. This polarization is characteristic of cells undergoing chemotaxis^{3,34}. Moreover, antibody-treated cells had a very low average CI, and a uniform distribution of trajectories (Figure 4), while control cells had significant clustering of trajectories in the gradient direction.

Others have previously demonstrated the inhibition of EGF-induced chemotaxis of MDA-MB-231 cells using anti-EGFR antibody in Boyden chambers¹⁶. Since the Boyden chamber is an end-point assay, random motility and directed motility cannot be visually distinguished. A series of conditions with different chemoattractant concentrations must be compared and evaluated using a checkerboard analysis in order to distinguish chemotaxis from chemokinesis. Consequently, the effect of antibody treatment can only be evaluated in regards to chemotaxis as a whole, not knowing if the antibody is interfering with motility, directional sensing, or both. The microfluidic chemotaxis chamber allows the migration process to be examined in real time, providing details of individual cell

trajectories as well as distributions of cell populations. We can thus evaluate both motility and directionality independent of each other. With this capability, we found that the anti-EGFR antibody targets both motility and directional sensing: in the presence of anti-EGFR, cells moved randomly with speeds similar to those at basal levels (non-EGF stimulated, data not shown). This verifies that the observed migratory response occurs specifically via EGFR, and that blockade of this receptor does not affect basal migration.

This approach can be used to categorize different types of inhibitors based on their mechanism of action. Antibodies act at the receptor level and block all the downstream signaling associated with the receptor, thus inhibiting the entire chemotactic response. Inhibitors that act further downstream may only block certain aspects of the chemotactic response, leaving the rest of the process intact. The mechanism of action of the inhibitor could be used as a measure of its effectiveness in metastasis therapy. One can envision a situation where a chemoattractant is specifically associated with cancer cell metastasis, and does not influence other cells. In such a case, inhibitors that completely block chemotaxis may be more effective, and may result in the best therapeutic outcome.

On the other hand, inhibiting only one aspect of chemotaxis may be desirable in certain cases. For example, it has been proposed that growth factor-induced migration is necessary for cancer cell invasion, but that adhesion-mediated basal migration is sufficient for normal cell function⁵. Evidence suggests that inhibition of PLC γ , a signaling molecule downstream of certain growth factor receptors, blocks growth factor-induced motility but leaves basal motility intact^{4, 24}. This would provide a therapeutic window, allowing metastatic cell migration to be targeted without interfering with normal processes. Using the microfluidic chemotaxis chamber, the effects of different inhibitors can be investigated in a quantitative manner, allowing comparisons of effectiveness based on quantitative data, in addition to qualitative observations.

Conclusion

We have developed a parallel-gradient microfluidic chemotaxis chamber capable of generating different experimental conditions in parallel, allowing individual cells to be investigated in detail while providing quantitative, statistically meaningful data for the whole cell population. Traditionally, drug candidates are evaluated in terms of their effects on proliferation using cell-based assays in microtiter plates. The microfluidic chemotaxis chamber described here represents a platform to investigate the effects of pharmaceutical compounds on cell migration (in terms of speed, chemotactic index, and directional orientation) and provides a means to evaluate their effectiveness in relation to metastasis. Coupled with conventional cell based assays, this approach may provide information about the different pathways involved in the migration of cancer cells, how they are modulated, and if there is any cross-talk that between pathways. This knowledge may result in novel approaches for treatment of metastasis that target cell motility.

Acknowledgements

This research is supported by the Whitaker Foundation, Concern Foundation (Grant No. CFCR-30575), and the Department of Defense (Grants No. DAMD17-03-1-0515 and No. DAMD17-03-1-0673).

References

1. Yang X, Corvalan J, Wang P, Roy C, Davis C. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. *J Leukoc Biol* 1999;66:401-10.
2. Maheshwari G, Wells A, Griffith LG, Lauffenburger DA. Biophysical integration of effects of epidermal growth factor and fibronectin on fibroblast migration. *Biophys J* 1999;76:2814-23.
3. Condeelis JS, Wyckoff JB, Bailly M, Pestell R, Lawrence D, Backer J, et al. Lamellipodia in invasion. *Semin Cancer Biol* 2001;11:119-28.
4. Kassis J, Lauffenburger DA, Turner T, Wells A. Tumor invasion as dysregulated cell motility. *Seminars in Cancer Biology* 2001;11:105-19.
5. Wells A, Kassis J, Solava J, Turner T, Lauffenburger DA. Growth factor-induced cell motility in tumor invasion. *Acta Oncol* 2002;41:124-30.
6. Wells A. Tumor invasion: Role of growth factor-induced cell motility. *Adv Cancer Res* 2000;78:31-101.
7. Wilkinson PC. Assays of leukocyte locomotion and chemotaxis. *Journal of Immunological Methods* 1998;216:139-53.
8. Dertinger SKW, Chiu DT, Jeon NL, Whitesides GM. Generation of gradients having complex shapes using microfluidic networks. *Anal. Chem.* 2001;73:1240-46.
9. Jeon NL, Baskaran H, Dertinger SKW, Whitesides GM, Van De Water L, Toner M. Neutrophil chemotaxis in linear and complex gradients of il-8 formed in a microfabricated device. *Nat Biotechnol* 2002;20:826-30.
10. Jeon NL, Dertinger SKW, Chiu DT, Whitesides GM. Generation of solution and surface gradients using microfluidic systems. *Langmuir* 2000;16:8311-16.
11. Wang S-J, Saadi W, Lin F, Nguyen CM-C, Jeon NL. Differential effects of egf gradient profiles on mda-mb-231 breast cancer cell chemotaxis. *Exp Cell Res* 2004;300:180-89.
12. Whitesides GM, Ostuni E, Takayama S, Jiang X, Ingber DE. Soft lithography in biology and biochemistry. *Annu Rev Biomed Eng* 2001;3:335-73.
13. Zar JH. Biostatistical analysis, ed. 3rd. Upper Saddle River, New Jersey: Prentice-Hall, Inc, 1996.
14. Bredin CG, Liu Z, Hauzenberger D, Klominek J. Growth-factor-dependent migration of human lung-cancer cells. *Int J Cancer* 1999;82:338-45.

15. Bailly M, Yan L, Whitesides GM, Condeelis JS, Segall JE. Regulation of protrusion shape and adhesion to the substratum during chemotactic responses of mammalian carcinoma cells. *Experimental Cell Research* 1998;241:285-99.
16. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW. Epidermal growth factor promotes mda-mb-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase c-dependent mechanism. *Cancer Research* 1999;59:5475-78.
17. Wyckoff JB, Segall JE, Condeelis JS. The collection of the motile population of cells from a living tumor. *Cancer Res* 2000;60:5401-4.
18. Lin F, Saadi W, Rhee SW, Wang S-J, Mittal S, Jeon NL. Generation of dynamic temporal and spatial concentration gradients using microfluidic devices. *Lab Chip* 2004;4:DOI: 10.1039/b313600k.
19. Levine MD, Liotta LA, Stracke ML. Stimulation and regulation of tumor cell motility in invasion and metastasis. *EXS* 1995;74:157-79.
20. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer* 2002;2:563-72.
21. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. *Nat Rev Cancer* 2003;3:55-63.
22. Steven Wiley H, Shvartsman SY, Lauffenburger DA. Computational modeling of the egf-receptor system: A paradigm for systems biology. *Trends in Cell Biology* 2003;13:43-50.
23. Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana C, et al. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. *Clin Cancer Res* 1995;1:19-31.
24. Turner T, Epps-Fung MV, Kassir J, Wells A. Molecular inhibition of phospholipase cgamma signaling abrogates du-145 prostate tumor cell invasion. *Clin Cancer Res* 1997;3:2275-82.
25. Dluz S, Higashiyama S, Damm D, Abraham J, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. Induction of mrna levels and secretion of active mitogen. *J. Biol. Chem.* 1993;268:18330-34.
26. Kume N, Gimbrone MJ. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. *J Clin Invest* 1994;93:907-11.
27. Peoples G, Blotnick S, Takahashi K, Freeman M, Klagsbrun M, Eberlein T. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: A potential pathologic role. *PNAS* 1995;92:6547-51.
28. Wyckoff JB, Jones JG, Condeelis JS, Segall JE. A critical step in metastasis: In vivo analysis of intravasation at the primary tumor. *Cancer Res* 2000;60:2504-11.
29. Woodburn J. The epidermal growth factor receptor and its inhibition in cancer therapy. *Pharmacol Ther* 1999;82:241-50.
30. Mendelsohn J, Baselga J. The egf receptor family as targets for cancer therapy. *Oncogene* 2000;19:6550-65.
31. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. *Endocr Relat Cancer* 2001;8:3-9.
32. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. *Clin Cancer Res* 2001;7:2958-70.
33. Fischer OM, Streit S, Hart S, Ullrich A. Beyond herceptin and gleevec. *Current Opinion in Chemical Biology* 2003;7:490-95.
34. Wyckoff JB, Insel L, Khazaie K, Lichtner RB, Condeelis JS, Segall JE. Suppression of ruffling by the egf receptor in chemotactic cells. *Experimental Cell Research* 1998;242:100-09.




Fig. 1 Schematic diagrams of the microfluidic chemotaxis chambers. (a) A single-gradient chemotaxis chamber that produces a polynomial gradient. The gradient was visualized by injecting media with 0% and 100% FITC-dextran from the inlets, with a volumetric flow rate ratio of 4:1 respectively. A fluorescence (pseudo colored) image of the migration channel and a corresponding intensity profile are shown at the bottom. (b) A parallel-gradient chemotaxis chamber producing two opposite gradients side by side. (c) A parallel-gradient chemotaxis chamber with a 100- μm barrier in the middle of the migration channel.




Fig. 2 Chemotactic response of MDA-MB-231 in 0-50 ng/ml and 0.1-6 ng/ml polynomial EGF gradients in parallel. (a) Average speed and chemotactic index (CI) values. Error bars represent standard error. Percentages indicate the number of cells that migrated towards the gradient. (b-c) Direction plots showing the distribution of migration angles, grouped in 10° intervals (wedges). The radius of each wedge indicates the number of cells that migrated in a particular direction. 157 cells and 170 cells were analyzed in 0-50 ng/ml and 0.1-6 ng/ml, respectively. A Rayleigh test shows that migration was directional in both ranges, with the mean angles of 87.4° and 53.9° for 0-50 ng/ml and 0.1-6 ng/ml, respectively. Arcs indicate 95% confidence intervals. In both plots, 90° is the direction of increasing EGF concentration. Cells that migrated a net distance of less than $25 \mu\text{m}$ were excluded.




Fig. 3 DIC images of MDA-MB-231 cells treated with anti-EGFR alongside untreated cells in 0-50 ng/ml EGF gradients after 3 hrs. In the absence of antibody treatment (left), most cells were polarized in the direction of increasing EGF concentration, while antibody-treated cells (right) were either unpolarized or randomly polarized.




Fig. 4 Anti-EGFR antibody inhibits chemotaxis of MDA-MB-231 in a 0-50 ng/ml EGF gradient. (a) Average speed and CI for antibody-treated cells, compared with control cells side by side. Error bars represent standard error. Percentages indicate the number of cells that migrated towards the gradient. (b-c) Direction plots showing the distribution of migration angles, grouped in 10° intervals (wedges). The radius of each wedge indicates the number of cells that migrated in that direction. 123 control cells and 101 anti-EGFR treated cells were analyzed. A Rayleigh test showed that untreated cells migrated directionally, with a mean angle of 74.8° (arc indicates 95% confidence), while antibody-treated cells had no directional preference. 90° is the direction of increasing EGF concentration.